Connect with us

Hi, what are you looking for?

Jewish Business News

Mergers & Acquisitions

UK company to acquire Perrigo for $20 billion

The pharmaceutical company’s share price is up 9 percent after the report to TASE

Perrigo John Hendrickson

 

The pharmaceutical company’s share price is up 9.1% on the TASE after reports that an unnamed UK company will acquire it for $20 billion.

Streetinsider.com said yestarday that the US drugmaker is close to being bought by a UK firm for $20 billion. Last night the share price rose 9.2% on the NYSE to $108, its highest price since April, giving a market cap of $15.5 billion.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.

Perrigo’s share price has fallen 41 percent over the years 2015-2016 after it was subject of a $29 billion hostile takeover bid from Mylan N.V.

Perrigo has been operating in Israel and traded on the TASE since its acquisition of Israeli company Agis Pharmaceuticals 10 years ago. Perrigo has 1, 200 employees and two plants in Israel.

 

Former CEO Joseph Papa, who left his position in April to become CEO at Valeant Pharmaceuticals International Inc. His successor is John Hendrickson.

 

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.